DAVID KAY previously was an official for the International Atomic Energy Agency in Vienna.
In an article yesterday about inspections of North Korea's nuclear sites, Mr. Kay was incorrectly identified as a former analyst for the Central Intelligence Agency.
(See: "Politics & Policy: Check of North Korea Nuclear Sites Won't Provide Comfort Clinton Wants" -- WSJ Jan. 31, 1994)
MYCOGEN Corp. said it expects to be profitable this year, following a restructuring of the company.
A Dec. 23 Enterprise article quoted analysts as indicating that the San Diego biotechnology company wouldn't be profitable in 1994.
(See: "Enterprise: Subterranean Insects Lift Young Biosys Off the Ground -- Agricultural Biotech Firm Depends on Nematodes for Its Natural Pesticides" -- WSJ Dec. 23, 1993)
ATLANTIC RICHFIELD Co.'s Vastar Resources Inc. unit will receive the proceeds from a proposed initial public offering of as much as 17.7% of Vastar stock outstanding.
An article yesterday incorrectly stated that Arco would receive the proceeds.
(See: "Business Brief: Arco's Vastar Unit Submits SEC Filing For Public Offering" -- WSJ Jan. 31, 1994)
GLASER CAPITAL Corp., Cincinnati, was the lead underwriter for the recently completed common stock offering of Future Healthcare Inc., also based in Cincinnati.
An article Wednesday incorrectly identified the lead underwriter as Monness, Crespi, Hardt & Co., New York.
(See: "Future Healthcare Offering" -- WSJ Jan. 26, 1994)
